Posts

MegaRobo raises nearly $200M

MegaRobo Technologies announced a financing round of nearly $200 million, with Oman’s sovereign wealth fund, the Oman Investment Authority, participating alongside CMB International and existing investors Asia Investment Capital, Granite Asia, and Sinovation Ventures. The company did not disclose its valuation. MegaRobo says it will use the funding to invest in core technology, expand its AI-for-science business internationally, and build systems connecting AI with physical laboratory and industrial work. It has reportedly raised about $600 million in total. Merck and Isomorphic Labs announced a research collaboration to discover small-molecule candidates for an undisclosed oncology target. Isomorphic will use its AI drug-design engine and selected Merck data to generate molecular designs; Merck will lead any resulting preclinical and clinical development, manufacturing, and commercialization. Financial terms of the Merck collaboration were not disclosed. Isomorphic is eligible f...

SELLAS AML vaccine posts Phase III survival benefit—promising, but not yet an approval

Commure acquires Elaborate to automate clinicians’ inbox work

Regeneron enters neurology with FDA approval of Livsayis for myasthenia gravis

FDA approves Sanofi’s Infilbray as first treatment for Type 3 Gaucher neurological symptoms

AbbVie and DISCO strike solid-tumor research deal worth up to $2.54B

nChroma halts hepatitis B trial and cuts workforce by about half

Jefferies biotech dispatch: AI, PI3Kα and protein degraders

Merck ends development of ArQule’s blood cancer drug

FDA rejects Summit’s ivonescimab application, citing modest benefit and added risks

Pfizer enters in vivo CAR-T with up to $2.6 billion Starna deal

GSK wins FDA approval for second Nuvalent lung cancer drug

CTAD 2026: Biogen and AriBio report signals of slower cognitive decline